Title:
EphA2アゴニストモノクローナル抗体およびその使用法
Document Type and Number:
Japanese Patent JP4585968
Kind Code:
B2
Abstract:
The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
Inventors:
Kinch, Michael, S.
Carls-Kinch, Kerry
Stewart, Jane, Sea.
Carls-Kinch, Kerry
Stewart, Jane, Sea.
Application Number:
JP2005506130A
Publication Date:
November 24, 2010
Filing Date:
May 12, 2003
Export Citation:
Assignee:
PURDUE RESEARCH FOUNDATION
International Classes:
C12N15/09; C07K16/24; C07K16/28; C07K16/30; C07K16/32; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12P21/08
Foreign References:
| WO2001012172A1 |
Other References:
Cell Growth & Differentiation,1999年,Vol.10,p.629-638
Attorney, Agent or Firm:
Yusuke Hiraki
Ishii Teiji
Satoshi Fujita
Ishii Teiji
Satoshi Fujita